Giant cell arteritis

Journal of Clinical Neuroscience

Volumn 16, Issue 10, 2009, Pages 1263-1268

  Chew, S S L ^a   Kerr, N M ^a   Danesh Meyer, H V ^a  

^a THE UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

Arteritis; Giant cell; Temporal

Indexed keywords

ACETYLSALICYLIC ACID; AZATHIOPRINE; C REACTIVE PROTEIN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DAPSONE; HLA DR4 ANTIGEN; INFLIXIMAB; INTERCELLULAR ADHESION MOLECULE 1; METHOTREXATE; METHYLPREDNISOLONE; PLACEBO; PREDNISONE;

ADAPTIVE IMMUNITY; ADJUVANT THERAPY; AORTA ARCH SYNDROME; BLOOD VESSEL BIOPSY; CLINICAL TRIAL; DIAGNOSTIC IMAGING; DIPLOPIA; DRUG DOSE REDUCTION; DRUG MEGADOSE; ERYTHROCYTE SEDIMENTATION RATE; GENETIC POLYMORPHISM; GIANT CELL ARTERITIS; HISTOPATHOLOGY; HUMAN; INCIDENCE; INNATE IMMUNITY; LABORATORY TEST; PATHOGENESIS; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RHEUMATIC POLYMYALGIA; SEX DIFFERENCE; VISUAL HALLUCINATION; VISUAL IMPAIRMENT;

GIANT CELL ARTERITIS; HUMANS;

EID: 68949140792     PISSN: 09675868     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jocn.2009.05.002     Document Type: Review

References (101)

1. Lawrence R.C., Helmick C.G., Arnett F.C., et al. Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthritis Rheum 41 (1998) 778-799
2. Smith C.A., Fidler W.J., and Pinals R.S. The epidemiology of giant cell arteritis. Report of a ten-year study in Shelby County, Tennessee. Arthritis Rheum 26 (1983) 1214-1219
3. Machado E.B.V., Michet C.J., Ballard D.J., et al. Trends in incidence and clinical presentation of temporal arteritis in Olmsted County, Minnesota, 1950-1985. Arthritis Rheum 31 (1988) 745-749
4. Hunder G.G. Epidemiology of giant-cell arteritis. Cleve Clin J Med 69 (2002) SII79-SII82
5. Bengtsson B.A., and Malmvall B.E. The epidemiology of giant cell arteritis including temporal arteritis and polymyalgia rheumatica. Incidences of different clinical presentations and eye complications. Arthritis Rheum 24 (1981) 899-904
6. Machado E.B., Michet C.J., Ballard D.J., et al. Trends in incidence and clinical presentation of temporal arteritis in Olmsted County, Minnesota, 1950-1985. Arthritis Rheum 31 (1988) 745-749
7. Baldursson O., Steinsson K., Bjornsson J., et al. Giant cell arteritis in Iceland. An epidemiologic and histopathologic analysis. Arthritis Rheum 37 (1994) 1007-1012
8. Gran J.T., and Myklebust G. The incidence of polymyalgia rheumatica and temporal arteritis in the county of Aust Agder, south Norway: a prospective study 1987-94. J Rheumatol 24 (1997) 1739-1743
9. Kemp A. Monozygotic twins with temporal arteritis and ophthalmic arteritis. Acta Ophthalmol (Copenh) 55 (1977) 183-190
10. Wernick R., Davey M., and Bonafede P. Familial giant cell arteritis: report of an HLA-typed sibling pair and a review of the literature. Clin Exp Rheumatol 12 (1994) 63-66
11. Barrier J., Bignon J.D., Soulillou J.P., et al. Increased prevalence of HLA-DR4 in giant-cell arteritis. N Engl J Med 305 (1981) 104-105
12. Weyand C.M., Hicok K.C., Hunder G.G., et al. The HLA-DRB1 locus as a genetic component in giant cell arteritis. Mapping of a disease-linked sequence motif to the antigen binding site of the HLA-DR molecule. J Clin Invest 90 (1992) 2355-2361
13. Salvarani C., Casali B., Boiardi L., et al. Intercellular adhesion molecule 1 gene polymorphisms in polymyalgia rheumatica/giant cell arteritis: association with disease risk and severity. J Rheumatol 27 (2000) 1215-1221
14. Hayreh S.S., Podhajsky P.A., Raman R., et al. Giant cell arteritis: validity and reliability of various diagnostic criteria. Am J Ophthalmol 123 (1997) 285-296
15. Smetana G.W., and Shmerling R.H. Does this patient have temporal arteritis?. JAMA 287 (2002) 92-101
16. McDonnell P.J., Moore G.W., Miller N.R., et al. Temporal arteritis. A clinicopathologic study. Ophthalmology 93 (1986) 518-530
17. Brack A., Martinez-Taboada V., Stanson A., et al. Disease pattern in cranial and large-vessel giant cell arteritis. Arthritis Rheum 42 (1999) 311-317
18. Klein R.G., Hunder G.G., Stanson A.W., et al. Large artery involvement in giant cell (temporal) arteritis. Ann Intern Med 83 (1975) 806-812
19. Evans J.M., O'Fallon W.M., and Hunder G.G. Increased incidence of aortic aneurysm and dissection in giant cell (temporal) arteritis. A population-based study. Ann Intern Med 122 (1995) 502-507
20. Calamia K.T., and Hunder G.G. Giant cell arteritis (temporal arteritis) presenting as fever of undetermined origin. Arthritis Rheum 24 (1981) 1414-1418
21. Salvarani C., Cantini F., and Hunder G.G. Polymyalgia rheumatica and giant-cell arteritis. Lancet 372 (2008) 234-245
22. Smeeth L., Cook C., and Hall A.J. Incidence of diagnosed polymyalgia rheumatica and temporal arteritis in the United Kingdom, 1990-2001. Ann Rheum Dis 65 (2006) 1093-1098
23. Salvarani C., Cantini F., Boiardi L., et al. Polymyalgia rheumatica and giant-cell arteritis. N Engl J Med 347 (2002) 261-271
24. Caselli R.J., Daube J.R., Hunder G.G., et al. Peripheral neuropathic syndromes in giant cell (temporal) arteritis. Neurology 38 (1988) 685-689
25. Caselli R.J., Hunder G.G., and Whisnant J.P. Neurologic disease in biopsy-proven giant cell (temporal) arteritis. Neurology 38 (1988) 352-359
26. Gonzalez-Gay M.A., Blanco R., Rodriguez-Valverde V., et al. Permanent visual loss and cerebrovascular accidents in giant cell arteritis: predictors and response to treatment. Arthritis Rheum 41 (1998) 1497-1504
27. Salvarani C., Giannini C., Miller D.V., et al. Giant cell arteritis: Involvement of intracranial arteries. Arthritis Rheum 55 (2006) 985-989
28. Huston K.A., Hunder G.G., Lie J.T., et al. Temporal arteritis: a 25-year epidemiologic, clinical, and pathologic study. Ann Intern Med 88 (1978) 162-167
29. Jonasson F., Cullen J.F., and Elton R.A. Temporal arteritis. A 14-year epidemiological, clinical and prognostic study. Scott Med J 24 (1979) 111-117
30. Hayreh S.S., Podhajsky P.A., and Zimmerman B. Ocular manifestations of giant cell arteritis. Am J Ophthalmol 125 (1998) 509-520
31. Liu G.T., Glaser J.S., Schatz N.J., et al. Visual morbidity in giant cell arteritis. Clinical characteristics and prognosis for vision. Ophthalmology 101 (1994) 1779-1785
32. Cornblath W.T., and Eggenberger E.R. Progressive visual loss from giant cell arteritis despite high-dose intravenous methylprednisolone. Ophthalmology 104 (1997) 854-858
33. Foroozan R., Deramo V.A., Buono L.M., et al. Recovery of visual function in patients with biopsy-proven giant cell arteritis. Ophthalmology 110 (2003) 539-542
34. Hayreh S.S., and Zimmerman B. Visual field abnormalities in nonarteritic anterior ischemic optic neuropathy: their pattern and prevalence at initial examination. Arch Ophthalmol 123 (2005) 1554-1562
35. Repka M.X., Savino P.J., Schatz N.J., et al. Clinical profile and long-term implications of anterior ischemic optic neuropathy. Am J Ophthalmol 96 (1983) 478-483
36. Danesh-Meyer H., Savino P.J., and Gamble G.G. Poor prognosis of visual outcome after visual loss from giant cell arteritis. Ophthalmology 112 (2005) 1098-1103
37. Henkind P., Charles N.C., and Pearson J. Histopathology of ischemic optic neuropathy. Am J Ophthalmol 69 (1970) 78-90
38. Gills J., and Wadsworth J. Retrograde transsynaptic degeneration of the inner nuclear layers of the retina. Invest Ophthalmol Vis Sci 6 (1967) 437
39. Danesh-Meyer H., Savino P.J., Spaeth G.L., et al. Comparison of arteritis and nonarteritic anterior ischemic optic neuropathies with the Heidelberg Retina Tomograph. Ophthalmology 112 (2005) 1104-1112
40. Danesh-Meyer H.V., Savino P.J., and Sergott R.C. The prevalence of cupping in end-stage arteritic and nonarteritic anterior ischemic optic neuropathy. Ophthalmology 108 (2001) 593-598
41. Fineman M.S., Savino P.J., Federman J.L., et al. Branch retinal artery occlusion as the initial sign of giant cell arteritis. Am J Ophthalmol 122 (1996) 428430
42. Lipton R.B., Rosenbaum D., and Mehler M.F. Giant cell arteritis causes recurrent posterior circulation transient ischemic attacks which respond to corticosteroid. Eur Neurol 27 (1987) 97-100
43. Tovilla-Canales J.L. Ocular manifestations of giant cell arteritis. Curr Opin Ophthalmol 9 (1998) 73-79
44. Aiello P.D., Trautmann J.C., McPhee T.J., et al. Visual prognosis in giant cell arteritis. Ophthalmology 100 (1993) 550-555
45. Ghanchi F.D., and Dutton G.N. Current concepts in giant cell (temporal) arteritis. Surv Ophthalmol 42 (1997) 99-123
46. Wagner A.D., Gerard H.C., Fresemann T., et al. Detection of Chlamydia pneumoniae in giant cell vasculitis and correlation with the topographic arrangement of tissue-infiltrating dendritic cells. Arthritis Rheum 43 (2000) 1543-1551
47. Elling P., Olsson A.T., and Elling H. [Synchronous variations in the incidence of temporal arteritis and polymyalgia rheumatica in Danish counties Association with epidemics of Mycoplasma pneumonia infection]. Ugeskr Laeger 159 (1997) 4123-4128
48. Nordborg C., Nordborg E., Petursdottir V., et al. Search for varicella zoster virus in giant cell arteritis. Ann Neurol 44 (1998) 413-414
49. Gabriel S.E., Espy M., Erdman D.D., et al. The role of parvovirus B19 in the pathogenesis of giant cell arteritis: a preliminary evaluation. Arthritis Rheum 42 (1999) 1255-1258
50. Weyand C.M., Goronzy J.J., Weyand C.M., et al. Giant-cell arteritis and polymyalgia rheumatica. Ann Intern Med 139 (2003) 505-515
51. Savage C.O., Harper L., and Holland M. New findings in pathogenesis of antineutrophil cytoplasm antibody-associated vasculitis. Curr Opin Rheumatol 14 (2002) 15-22
52. Weyand C.M., and Goronzy J.J. Arterial wall injury in giant cell arteritis. Arthritis Rheum 42 (1999) 844-853
53. Wagner A.D., Bjornsson J., Bartley G.B., et al. Interferon-gamma-producing T cells in giant cell vasculitis represent a minority of tissue-infiltrating cells and are located distant from the site of pathology. Am J Pathol 148 (1996) 1925-1933
54. Weyand C.M., Schonberger J., Oppitz U., et al. Distinct vascular lesions in giant cell arteritis share identical T cell clonotypes. J Exp Med 179 (1994) 951-960
55. Martinez-Taboada V., Hunder N.N., Hunder G.G., et al. Recognition of tissue residing antigen by T cells in vasculitic lesions of giant cell arteritis. J Mol Med 74 (1996) 695-703
56. Weyand C.M., Wagner A.D., Bjornsson J., et al. Correlation of the topographical arrangement and the functional pattern of tissue-infiltrating macrophages in giant cell arteritis. J Clin Invest 98 (1996) 1642-1649
57. Rittner H.L., Kaiser M., Brack A., et al. Tissue-destructive macrophages in giant cell arteritis. Circ Res 84 (1999) 1050-1058
58. Kaiser M., Weyand C.M., Bjornsson J., et al. Platelet-derived growth factor, intimal hyperplasia, and ischemic complications in giant cell arteritis. Arthritis Rheum 41 (1998) 623-633
59. Weyand C.M., Tetzlaff N., Bjornsson J., et al. Disease patterns and tissue cytokine profiles in giant cell arteritis. Arthritis Rheum 40 (1997) 19-26
60. Mortensen R.F. C-reactive protein, inflammation, and innate immunity. Immunol Res 24 (2001) 163-176
61. Streetz K.L., Wustefeld T., Klein C., et al. Mediators of inflammation and acute phase response in the liver. Cell Mol Biol (Noisy-le-grand) 47 (2001) 661-673
62. Wagner A.D., Goronzy J.J., and Weyand C.M. Functional profile of tissue-infiltrating and circulating CD68+ cells in giant cell arteritis. Evidence for two components of the disease. J Clin Invest 94 (1994) 1134-1140
63. Weyand C.M., and Bartley G.B. Giant cell arteritis: new concepts in pathogenesis and implications for management. Am J Ophthalmol 123 (1997) 392-395
64. Lie J.T. Histopathologic specificity of systemic vasculitis. Rheum Dis Clin North Am 21 (1995) 883-909
65. Weyand C.M., Ma-Krupa W., and Goronzy J.J. Immunopathways in giant cell arteritis and polymyalgia rheumatica. Autoimmun Rev 3 (2004) 46-53
66. Hunder G.G., Bloch D.A., Michel B.A., et al. The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. Arthritis Rheum 33 (1990) 1122-1128
67. Jacobson D.M., and Slamovits T.L. Erythrocyte sedimentation rate and its relationship to hematocrit in giant cell arteritis. Arch Ophthalmol 105 (1987) 965-967
68. Miller A., Green M., and Robinson D. Simple rule for calculating normal erythrocyte sedimentation rate. Br Med J (Clin Res Ed) 286 (1983) 266
69. Kyle V., Cawston T.E., and Hazleman B.L. Erythrocyte sedimentation rate and C reactive protein in the assessment of polymyalgia rheumatica/giant cell arteritis on presentation and during follow up. Ann Rheum Dis 48 (1989) 667-671
70. Parikh M., Miller N.R., Lee A.G., et al. Prevalence of a normal C-reactive protein with an elevated erythrocyte sedimentation rate in biopsy-proven giant cell arteritis. Ophthalmology 113 (2006) 1842-1845
71. Krishna R., and Kosmorsky G.S. Implications of thrombocytosis in giant cell arteritis. Am J Ophthalmol 124 (1997) 103
72. Price N., and Clearkin L.G. Thrombocytosis and giant cell arteritis. Lancet 343 (1994) 672
73. Foroozan R., Danesh-Meyer H., Savino P.J., et al. Thrombocytosis in patients with biopsy-proven giant cell arteritis. Ophthalmology 109 (2002) 1267-1271
74. Weiss L.M., Gonzalez E., Miller S.B., et al. Severe anemia as the presenting manifestation of giant cell arteritis. Arthritis Rheum 38 (1995) 434-436
75. Brittain G.P., McIlwaine G.G., Bell J.A., et al. Plasma viscosity or erythrocyte sedimentation rate in the diagnosis of giant cell arteritis?. Br J Ophthalmol 75 (1991) 656-659
76. von Knorring J. Treatment and prognosis in polymyalgia rheumatica and temporal arteritis. A ten-year survey of 53 patients. Acta Med Scand 205 (1979) 429-435
77. Weyand C.M., Fulbright J.W., Hunder G.G., et al. Treatment of giant cell arteritis: interleukin-6 as a biologic marker of disease activity. Arthritis Rheum 43 (2000) 1041-1048
78. Espinosa G., Tassies D., Font J., et al. Antiphospholipid antibodies and thrombophilic factors in giant cell arteritis. Semin Arthritis Rheum 31 (2001) 12-20
79. Liozon E., Roblot P., Paire D., et al. Anticardiolipin antibody levels predict flares and relapses in patients with giant-cell (temporal) arteritis. A longitudinal study of 58 biopsy-proven cases. Rheumatology (Oxford) 39 (2000) 1089-1094
80. Huston K.A., and Hunder G.G. Giant cell (cranial) arteritis: a clinical review. Am Heart J 100 (1980) 99-105
81. Ray-Chaudhuri N., Kine D.A., Tijani S.O., et al. Effect of prior steroid treatment on temporal artery biopsy findings in giant cell arteritis. Br J Ophthalmol 86 (2002) 530-532
82. Su G.W., Foroozan R., and Yen M.T. Quantitative analysis of temporal artery contraction after biopsy for evaluation of giant cell arteritis. Can J Ophthalmol 41 (2006) 500-503
83. Niederkohr R.D., and Levin L.A. Management of the patient with suspected temporal arteritis a decision-analytic approach. Ophthalmology 112 (2005) 744-756
84. Siatkowski R.M., Gass J.D., Glaser J.S., et al. Fluorescein angiography in the diagnosis of giant cell arteritis. Am J Ophthalmol 115 (1993) 57-63
85. Hunder G.G., and Weyand C.M. Sonography in giant-cell arteritis. N Engl J Med 337 (1997) 1385-1386
86. Atalay M.K., and Bluemke D.A. Magnetic resonance imaging of large vessel vasculitis. Curr Opin Rheumatol 13 (2001) 41-47
87. de Leeuw K., Bijl M., and Jager P.L. Additional value of positron emission tomography in diagnosis and follow-up of patients with large vessel vasculitides. Clin Exp Rheumatol 22 (2004) S21-S26
88. Hall E.D. High-dose glucocorticoid treatment improves neurological recovery in head-injured mice. J Neurosurg 62 (1985) 882-887
89. Hayreh S.S., and Zimmerman B. Visual deterioration in giant cell arteritis patients while on high doses of corticosteroid therapy. Ophthalmology 110 (2003) 1204-1215
90. Proven A., Gabriel S.E., Orces C., et al. Glucocorticoid therapy in giant cell arteritis: duration and adverse outcomes. Arthritis Rheum 49 (2003) 703-708
91. Goodman Jr. B.W. Temporal arteritis. Am J Med 67 (1979) 839-852
92. Hernandez-Rodriguez J., Garcia-Martinez A., Casademont J., et al. A strong initial systemic inflammatory response is associated with higher corticosteroid requirements and longer duration of therapy in patients with giant-cell arteritis. Arthritis Rheum 47 (2002) 2935
93. Hoffman G.S., Cid M.C., Hellmann D.B., et al. A multicenter, randomized, double-blind, placebo-controlled trial of adjuvant methotrexate treatment for giant cell arteritis. Arthritis Rheum 46 (2002) 1309-1318
94. Spiera R.F., Mitnick H.J., Kupersmith M., et al. A prospective, double-blind, randomized, placebo controlled trial of methotrexate in the treatment of giant cell arteritis (GCA). Clin Exp Rheumatol 19 (2001) 495-501
95. Hoffman G.S., Cid M.C., Rendt-Zagar K.E., et al. Infliximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis: a randomized trial. Ann Intern Med 146 (2007) 621-630
96. Lee M.S., Smith S.D., Galor A., et al. Antiplatelet and anticoagulant therapy in patients with giant cell arteritis. Arthritis Rheum 54 (2006) 3306-3309
97. Nesher G., and Sonnenblick M. Steroid-sparing medications in temporal arteritis - report of three cases and review of 174 reported patients. Clin Rheumatol 13 (1994) 289-292
98. De Silva M., and Hazleman B.L. Azathioprine in giant cell arteritis/polymyalgia rheumatica: a double-blind study. Ann Rheum Dis 45 (1986) 136-138
99. Nuenninghoff D.M., and Matteson E.L. The role of disease-modifying antirheumatic drugs in the treatment of giant cell arteritis. Clin Exp Rheumatol 21 (2003) S29-S34
100. Morris C.R., and Scheib J.S. Fatal myocardial infarction resulting from coronary arteritis in a patient with polymyalgia rheumatica and biopsy-proved temporal arteritis. A case report and review of the literature. Arch Intern Med 154 (1994) 1158-1160
101. Hunder G.G. Giant cell arteritis and polymyalgia rheumatica. In: Kelley W.N., Harris E.D., and Ruddy S. (Eds). Textbook of Rheumatology. 4th ed. (1993), W.B. Saunders, Philadelphia, PA 1103-1112